• Profile
Close

Elderly patients with metastatic neuroendocrine tumors are undertreated and have shorter survival: The LyREMeNET study

Neuroendocrinology Oct 11, 2019

Lemelin A, Maucort-Boulch D, Castel-Kremer E, et al. - Since the incidence of neuroendocrine tumors (NETs) is rising, particularly in elderly patients, researchers desired to know about the features, treatment pattern, and outcomes of metastatic NET patients. Consecutive metastatic NET patients (mNETs), diagnosed between January 1990 and December 2017, were included in the Lyon Real-life Evidence in Metastatic NeuroEndocrine Tumors study. Patients ≥ 70 years old (yo) were compared to patients < 70 yo. In total, 866 patients were involved, 198 were ≥ 70 yo. No significant difference was found in features except that elderly patients had more frequently synchronous metastasis. Patients ≥ 70 yo have worse survival, die frequently from their disease, and are undertreated in contrast to younger patients. The most common cause of death was associated with the progression of the disease.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay